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Introduction
 The burden of disease caused by cancer presents 
significant challenges to individuals, families, and society. 
According to the National Statistics Office, the average 
mortality rate from cancer was 142.8 people per 100,000 
in 2011. Cancer was the leading cause (Statistics Korea 
and Ministry of Gender Equality and Family, 2012). 
Cancer is the most crucial factor threatening public health. 
The socioeconomic burden caused by cancer continues 
to increase (Jung, 2008). The burden from increased 
incidence of cancer and cancer-related mortality are also 
increasing (National Cancer Institute, 2013) due to aging 
of the population (Statistics Korea, 2013a), changes in 
eating habits (Hong et al., 2011), environmental changes 
(Kim et al., 2006), high smoking rate (Statistics Korea, 
2013b), and reduced physical activity (Korea Centers for 
Disease Control and Prevention, 2013).
 As the cancer burden grows, there are two reasons that 
measuring the burden according to specific cancer site is 
important. The first reason is that measuring burden of 
specific cancer sites can differentiate fatal and nonfatal 
cancers. The second reason is that policy makers can seek 
strategies to prioritize cancers, which may help to more 
efficiently reduce the cancer burden. 
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Abstract
 Background: The purpose of this study was to develop a single measure of cancer burden (SMCB), which can 
prioritize cancer sites by considering incidence and mortality. Materials and Methods: Incidence data from 1999 
to 2010 were obtained from the Korea Central Cancer Registry. Mortality data from 1999 to 2010 were obtained 
from Statistics Korea. The SMCB was developed by adding incidence and mortality scores. The respective scores 
were given such that incidence and mortality were classified by ten ranges of equal intervals. Results: According 
to the SMCB in 2010, stomach cancer ranked 1st in males with 20 points, and colorectal cancer was 2nd with 11 
points. Breast cancer and thyroid cancer were joint 1st with 11 points for females. The SMCB for females was 
less than that for males. The burden of stomach cancer was 1st in males from 1999-2010. The incidences of 
lung cancer and liver cancer decreased, whereas thyroid cancer and colon cancer increased during the period. 
Breast cancer and thyroid cancer burden showed tendencies to increase in females. Comparison of SMCB with 
disability-adjusted life years (DALY) and socioeconomic costs in 2005 showed that the top five cancer sites were 
similar, but there were differences in the size of the cancer burden. Conclusions: The SMCB indicated that the 
burdens of stomach cancer in males and thyroid and breast cancers in females were large. The single measure 
showed an advantage, reflected as the equivalent dimensions of incidence and mortality, whereas DALY and 
economic costs showed tendencies to reflect premature death. 
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 Cancer burden can be measured by three methods. 
The traditional method is to identify burden based on 
epidemiologic indicators, such as incidence, mortality, 
and prevalence. The second method is to measure cancer 
burden by socioeconomic burden. The final method is to 
measure burden by disability-adjusted life years (DALY), 
which takes quality of life into consideration (Prüss-Üstün 
et al., 2003; Yoon and Bae, 2004; Yoon et al., 2012). 
 This study will discuss the traditional epidemiologic 
method of measuring cancer burden by incidence and 
mortality. After the comprehensive framework of global 
burden of disease (GBD) was developed in 1990, GBD 
researchers tried to find a single measure of disease burden 
by considering death and disability due to disease and 
injury (World Bank, 1993). Similarly, a single measure that 
considers incidence and mortality is needed to measure 
the epidemiological burden of cancer. 
 Most previous studies that dealt with incidence (Datta 
et al., 2010; Eser et al., 2010) and mortality compared 
these two parameters according to cancer site (Lin and 
Chen, 2009). Some studies examined annual trends for 
specific cancer sites and ranked findings according to 
incidence and mortality(Kumar and Yeole, 2005; Bener 
et al., 2007). Alternatively, some studies ranked cancer 
sites according to incidence and mortality (Yancik, 1997; 
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Shibuya et al., 2002; Kamangar et al., 2006; Ferlay et 
al., 2010; Jemal et al., 2010). However, incidence and 
mortality are not usually ranked the same for individual 
cancer sites. For example, cancer sites are classified into 
24 cancers by the International Statistical Classification 
of Diseases and Related Health Problems, 10th revision 
(ICD-10) (Centers for disease control and prevention, 
2013). The incidence of thyroid cancer was ranked 1st in 
females (Ministry of Health And Welfare, 2013b), but the 
mortality ranking for thyroid cancer was 15th (Ministry 
of Health And Welfare, 2013a). The burden of thyroid 
cancer was considered greatest if only incidence was 
considered. However, the burden of thyroid cancer was 
low if only mortality was considered. It is difficult to 
prioritize cancers with these approaches. Thus, previous 
studies had limitations, because incidence and mortality 
were not simultaneously considered.
 Therefore, the aims of this study were to develop a 
single measure of cancer burden, which can determine 
priority for any cancer by comprehensively considering 
incidence and mortality. Thus, an indicator that anyone can 
easily use can be created with this simple and reasonable 
method.
Materials and Methods
 Incidence data from 1999 to 2010 were obtained for 
approximately 24 cancers from the Ministry of Health and 
Welfare and for about 61 cancers from the Korea Central 
Cancer Registry (Ministry of Health And Welfare, 2013b). 
Mortality data from 1999 to 2010 were obtained for 103 
causes of death and 236 causes of death from Statistics 
Korea (Ministry of Health And Welfare, 2013a). 
 Causes of death were coded and classified according to 
ICD-10 (Centers for disease control and prevention, 2013). 
Incidence data were coded and classified according to the 
International Classification of Diseases for Oncology, 
3rd edition. Diseases related to cancer were reclassified 
into 22 cancers to allow us to make comparisons. Cancer 
cases were reclassified as follows: cancers of the lip, oral 
cavity, and pharynx (C00-C14), esophageal cancers (C15), 
stomach cancer (C16), cancers of the colon, rectum, and 
anus (C18-C21), liver and intrahepatic bile duct (liver) 
cancers (C22), cancers in the gallbladder or other parts 
of the biliary tract (gallbladder) (C23-C24), pancreatic 
cancers (C25), cancers of the larynx (C32), lung and 
bronchial (lung) cancers (C33-C34), breast cancers 
(C50), cervical uterine cancers (C53), corpus uterine 
and other unknown uterine cancers (C54-C55), ovarian 
cancers (C56), prostate cancers (C61), cancers of the 
male reproductive organ except prostate (C60, C62-C63), 
kidney cancers (C64), bladder cancers (C67), brain and 
central nervous system cancers (C70-C72), thyroid 
cancers (C73), non-Hodgkin’s lymphoma (C82-C85, 
C96), multiple myeloma (C90), and leukemia (C91-C95). 
Hodgkin’s lymphoma was excluded, because the mortality 
could not be estimated.
 A single measure was developed by considering both 
incidence and mortality. The method was developed 
as follows. Age-adjusted incidence and age-adjusted 
mortality were estimated from 1999 to 2010 with the mid-
year population in 2005. Population data were obtained 
from the resident registration population, which was 
reported by Statistics Korea. 
 A maximum value of age-adjusted incidence for the 
whole population was identified in 2010. The maximum 
value of incidence was 67.5 cases of thyroid cancer per 
100,000 people. Based on this value, the range was set 
by dividing data into 10 equal intervals from 0 to 67.5. 
Age-adjusted incidence was scored by sex and cancer site. 
The range of 0 to less than 6.75 was scored with 1 point. 
The range of 6.75 to less than 13.5 was scored as 2 points, 
and the range of 13.5 to less than 20.25 was assigned 3 
points. Thus, the score was given 9 points, and 10 points 
were assigned at values greater than 60.75 (6.75×9).
 Mortality data were scored in a similar manner. The 
maximum value of age-adjusted mortality for the whole 
population was identified in 2010. The maximum value 
of mortality was 25.3 cases of lung cancer per 100,000 
people. Based on this value, the range was set by dividing 
data into 10 equal intervals from 0 to 25.3. Age-adjusted 
mortality was scored by sex and cancer site.
 The scores for incidence and mortality were added 
by sex and cancer site. Scores ranged from 2 points to 
20 points. Rank was determined by sex and cancer site 
according to the sum of scores.
 Respective rank was determined by sex and cancer 
site according to age-adjusted incidence and age-adjusted 
mortality. The rank of single measure and the respective 
rank by age-adjusted incidence and age-adjusted mortality 
were compared. Scores were assigned for annual age-
adjusted incidence and annual age-adjusted mortality by 
the same method. The trend was analyzed by year, sex, 
and cancer site according to the single measure of cancer 
burden. 
 Finally, single measure of cancer burden was compared 
with previous data on DALY and economic cancer burden.
Results 
 Comparison of ranking by incidence and mortality with 
ranking by Single Measure of Cancer Burden (SMCB) is 
shown in Table 1. Stomach cancer was the most frequent 
cancer among Korean males in 2010 with 71.2 cases per 
100,000 (Table 1). The order of ranking was lung cancer 
(50.8), liver cancer (41.3), colon cancer (26.5), and thyroid 
cancer (23.3). The age-adjusted mortality for lung cancer 
was 45.7 people per 100,000. Age-adjusted mortalities per 
100,000 people according to cancer site were lung cancer 
(45.7), liver cancer (31.3), stomach cancer (25.8), colon 
cancer (17.3), and pancreatic cancer (9.0). In the case of 
thyroid cancer, the incidence was ranked higher than 5th, 
and the mortality rank was 18th. According to the rankings 
for incidence and mortality, cancer burden by cancer 
site showed a different pattern. The burden of stomach 
cancer was greatest according to the SMCB score of 20, 
which included 10 points for incidence and 10 points for 
mortality. The SMCB scores were in the following order. 
Lung cancer had 18 points with 8 points for incidence and 
10 points for mortality. Liver cancer had 17 points with 
7 points for incidence and 10 points for mortality. Colon 
cancer had 11 points with 4 points for incidence and 7 
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points for mortality. Finally, pancreatic cancer had 6 points 
with 2 points for incidence and 4 points for mortality. 
 Thyroid cancer had the highest incidence in females 
in 2010 with 111.5 people per 100,000 (Table 1). The 
rankings were in the following order: breast cancer 
(51.1), stomach cancer (30.3), colon cancer (17.1), and 
lung cancer (16.9). Age-adjusted mortalities per 100,000 
people according to cancer site were lung cancer (11.3), 
stomach cancer (10.1), colon cancer (9.3), liver cancer 
(8.1), and breast cancer (6.4). The greatest cancer burden 
according to SMCB score was thyroid cancer with an 
incidence of 10 points and mortality of 1 point. Breast 
cancer had an incidence score of 8 points and mortality 
score of 3 points, which gave an SMCB score of 11 
points. The SMCB scores were in the following order. 
Stomach cancer had 9 points with 5 points for incidence 
and 4 points for mortality. Lung cancer had 8 points with 
3 points for incidence and 5 points for mortality. Colon 
cancer had 7 points with 3 points for incidence and 4 points 
for mortality. Thyroid cancer and breast cancer were tied 
for the SMCB. However, the incidence rank and mortality 
rank for breast cancer were 2nd and 5th, respectively, 
whereas the incidence rank and mortality rank for thyroid 
cancer were 1st and 15th, respectively. Breast cancer was 
ranked in the top five for both incidence and mortality. In 
contrast, thyroid cancer was in the top five for incidence 
only.
 Comparison of the cancer burden by SMCB for males 
and females showed that stomach cancer ranked 1st in 
males with 20 points. Breast cancer and thyroid cancer 
tied for 1st in females with 11 points each. The burden of 
colon cancer in males also received a score of 11 points. 
Thus, the cancer burden in females appeared to be less 
than the cancer burden in males.
 Annual trends for cancer burden according to sex and 
cancer site are presented in Figure 1. The annual cancer 
burden was estimated with the same standard from 2010. 
The burden of stomach cancer in males was the same by 
year. The burdens of lung cancer and liver cancer showed 
tendencies to decrease, whereas thyroid cancer and colon 
cancer showed the opposite trends. Although the burden 
of thyroid cancer was modest in comparison with other 
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Table 1. Cancer-Specific Burden in 2010, for Male and Female
Cancer sites§  Incidence* Mortality** SMCB Score Rank comparison
   Total     Incidence    Mortality  Incidence†    Mortality‡    SMCB#
Male: 
   Stomach (C16) 71.2 25.9 20 10 10 1 3 1
   Lung (C33-C34) 50.8 45.7 18 8 10 2 1 2
   Liver (C22) 41.3 31.3 17 7 10 3 2 3
   Colon, rectum, and anus (C18-C21) 26.5 17.3 11 4 7 4 4 4
   Pancreas (C25) 8.8 9.0 6 2 4 9 5 5
   Gallbladder (C23-C24) 8.7 7.1 5 2 3 10 6 6
   Thyroid (C73) 23.3 0.4 5 4 1 5 18 6
   Esophagus (C15) 7.1 5.  4 2 2 12 7 8
   Bladder (C67) 9.4 3.4 4 2 2 7 9 8
   Non-Hodgkin’s lymphoma (C82-C85,C96) 7.9 3.2 4 2 2 11 10 8
   Prostate (C61) 13.0 2.0 3 2 1 6 14 11
   Kidney (C64) 8.9 2.1 3 2 1 8 13 11
   Lip, oral cavity, and pharynx (C00-C14) 6.6 2.8 3 1 2 13 11 11
   Leukemia (C91-C95) 5.8 3.6 3 1 2 14 8 11
   Larynx (C32) 3.7 1.4 2 1 1 15 17 15
   Breast (C50) 0.0 0.0 2 1 1 19 19 15
   Male reproductive organ except prostate (C60-C63) 0.5 2.0 2 1 1 18 14 15
   Brain and central nervous system (C70-C72) 3.5 2.5 2 1 1 16 12 15
   Multiple myeloma (C90) 2.1 1.5 2 1 1 17 16 15
Female: 
   Breast (C50) 51.1 6.4 11 8 3 2 5 1
   Thyroid (C73) 111.5 0.6 11 10 1 1 15 1
   Stomach (C16) 30.3 10.1 9 5 4 3 2 3
   Lung (C33-C34) 16.9 11.3 8 3 5 5 1 4
   Colon, rectum, and anus (C18-C21) 17.1 9.3 7 3 4 4 3 5
   Liver (C22) 11.8 8.1 6 2 4 6 4 6
   Panceras (C25) 5.7 5.5 4 1 3 9 6 7
   Cervix uteri (C53) 7 2.7 4 2 2 7 8 7
   Gallbladder (C23-C24) 6.4 4.6 3 1 2 8 7 9
   Larynx (C32) 0 0 2 1 1 20 20 10
   Esophagus (C15) 0.6 0.1 2 1 1 19 19 10
   Multiple myeloma (C90) 1.5 0.9 2 1 1 18 13 10
   Lip, oral cavity, and pharynx (C00-C14) 2.5 0.5 2 1 1 16 17 10
   Bladder (C67) 1.7 0.6 2 1 1 17 15 10
   Corpus uteri (c54-c55) 3.1 0.9 2 1 1 14 13 10
   Ovary (C56) 3.7 1.6 2 1 1 13 11 10
   Kidney (C64) 3.4 0.5 2 1 1 13 17 10
   Brain and central nervous system (C70-C72) 2.7 1.5 2 1 1 15 12 10
   Leukemia (C91-C95) 4.2 2.3 2 1 1 11 9 10
   Non-Hodgkin’s lymphoma (C82-C85,C96) 5.7 1.8 2 1 1 9 10 10
*Incidence, **Mortality: age-adjusted incidence and mortality standardized as mid-year population in 2005, SMCB scores: incidence score+mortality score; respective 
score was given that incidence and mortality were reclassified by 10 ranges using equal interval from 0 to the maximum value in 2010; †Incidence: arranged by cancer-
specific incidence (1st-19th); ‡Mortality: arranged by cancer-specific mortality(1st-19th); #SMCB: arranged by SMCB scores(1st-19th); §: rearranged by SMCB scores
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Figure 1. Annual Cancer-Specific SMCB (1999-2010) for A) Males and B) Females
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Table 2. Comparison SMCB with DALY and Social-Economic Burden in 2005 and 2010
Cancer sites§ 2005 2010
 SMCB Scores DALY*  Social-economic costs‡ SMCB Scores DALY 
Lung (C33-C34) 16 217 1,653,039  16 239
Stomach (C16) 19 245 2,377,698  15 292
Liver (C22) 14 237 2,445,189  12 254
Colon, rectum, and anus (C18-C21) 11 137 1,362,989  12 214
Thyroid (C73) 5 14 514,354  11 50
Breast (C50) 6 71 947,520  6 111
Pancreas (C25) 5 54 411,103  5 72
Gallbladder (C23-C24) 5 54 375,684  5 58
Cervix uteri (C53) 4 35 360,202  4 43
Leukemia (C91-C95) 3 52 588,505  3 52
Non-Hodgkin’s lymphoma (C82-C85,C96) 2 31 382,085  3 39
Prostate (C61) 3 13 123,370  3 28
Brain and central nervous system (C70-C72) 2 37 365,667  2 39
Ovary (C56) 2 22 211,536  2 31
Esophagus (C15) 3 24 202,456  2 24
Lip, oral cavity, and pharynx(C00-C14) 2 24 111,875  2 32
Kidney (C64) 2 16 185,182  2 26
Bladder (C67) 2 16 173,258  2 26
Larynx (C32) 2 10 104,980  2 11
Multiple myeloma (C90) 2 9 98,670  2 14
Corpus uteri (C54-C55) 2 8 65,122  2 16
Male reproductive organ except prostate (C60-C63)† 2 1 17,336  2 2
*DALY: replaced the average of 2004 and 2006 due to not available data of 2005 (data: Park et al. the analysis and reduction strategies of cancer burden in Korea. Korean 
Foundation fro cancer Research, 2012), unit of DALY: person-year/one hundred thousand people); ‡Social-economic burden: including medical care and non-medical 
expenses, morbidity and mortality cost (data: Kim et al. economic burden of cancer in South Korea for the year 2005. Journal of Preventive Medicine and Public Health, 
2009), unit of social-economic costs: million-won; †Corresponds only testis cancer (C60) in DALY and social-economic burden; §Rearranged by SMCB scores
cancers, the burden continued to grow. The burden of 
colon cancer increased steadily until 2004, at which point 
it has been stable.
 The burden of stomach cancer in females showed a 
tendency to decrease from 13 points in 1999 to 9 points 
in 2010. The burdens of breast cancer and thyroid cancer 
showed tendencies to increase. In particular, the growth 
rate for thyroid cancer burden was larger than that for 
breast cancer. The burden of colon cancer was not as great 
as that of breast cancer or thyroid cancer, but it was one 
of the cancers whose burden continued to increase. 
 SMCB was compared to two previous studies in 
which the annual estimated DALY by cancer site and 
socioeconomic costs of cancer burden were examined to 
validate SMCB (Table 2). The burden of lung cancer by 
DALY and SMCB was greatest in 2005, but the greatest 
socioeconomic burden by cancer site was for liver cancer. 
Cancer burden according to DALY, socioeconomic costs, 
and SMCB for the top five cancers were the same in 2005, 
but there were differences in the size of cancer burden. 
Cancer burden rankings according to SMCB scores were 
the following. Thyroid cancer was ranked 6th, followed 
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by pancreatic cancer, gallbladder cancer (5 points), and 
cancer of the uterine cervix (4 points). Cancer burdens 
by socioeconomic costs were in the following order. 
Leukemia was 1st (588,505 million won) followed by 
thyroid cancer (514,354 million won) and pancreatic 
cancer (411,103 million won). Cancer burden by DALY 
ranked pancreatic cancer 1st, followed by gallbladder 
cancer (54 person-years) and leukemia (52 person-years). 
The DALY for thyroid cancer were 14 person-years, which 
indicated a relatively smaller burden for thyroid cancer in 
comparison to other methods.
 The burdens of prostate cancer and leukemia by SMCB 
were each 3 points. However, the burdens of prostate 
cancer and leukemia by DALY were 13 person-years 
and 52 person-years, respectively. The burdens for these 
cancers according to socioeconomic costs were 123,770 
million won and 588,505 million won, respectively. The 
burden of leukemia was more than four times larger. 
Cancer burden by SMCB was distributed by 2 points 
for the remaining cancers. In contrast, cancer burden by 
DALY was distributed from 1 person-year to 25 person-
years except in non-Hodgkin’s lymphoma and brain 
cancer. Cancer burden by socioeconomic burden was 
distributed from 17,336 million won to 211,536 million 
won.
 
Discussion
We compared cancer burden according to incidence 
and mortality with cancer burden assessed by a single 
measure. This single measure considered both incidence 
and mortality to determine the priority of these factors in 
epidemiologic disease burden. This study also compared 
SMCB with DALY and socioeconomic costs, which were 
estimated from previous studies, to validate development 
of the SMCB method. There are several discussion points 
regarding development of a single measure. 
First, validation of the single measure should be 
discussed. As mentioned in the introduction of this study, 
cancer burden may be measured by three methods. The 
first method is the traditional method, which examines 
epidemiologic indicators, such as incidence, mortality, 
and prevalence. The second method is to estimate 
socioeconomic costs due to diseases. The final method 
is to measure DALY (Prüss-Üstün et al., 2003; Yoon and 
Bae, 2004). These three methods share the same goal of 
measuring cancer burden based on incidence, mortality, 
and prevalence. The DALY and socioeconomic methods 
may differ slightly, in which case comparisons can be 
based on DALY estimation studies (Park and Park, 2012; 
Park et al., 2013) and the socioeconomic costs study (Kim 
et al., 2009). 
In the DALY estimation studies (Park and Park, 2012; 
Park et al., 2013), DALY were estimated as the sum of 
the years of life lost (YLLs), which were defined as the 
quantity of premature death or fatal health outcomes, and 
the years lived with disability (YLDs), or the quality of 
disabled life or non-fatal health outcomes. YLL and YLD 
take into consideration life expectancy, age-weighting, 
and discount rate by time preference. So DALY highlight 
premature mortality (Murthy et al., 2010).
In the socioeconomic costs study (Kim et al., 2009), 
total costs related to cancer were classified into direct costs 
and indirect costs. Directs costs included both medical and 
non-medical care expenses, and indirect costs consisted of 
morbidity, mortality, and the caregiver’s time costs. Both 
studies estimated the years of life lost and the costs of 
premature death in connection with cancer burden. Indirect 
costs, which combine morbidity costs and mortality costs, 
are usually greater than direct costs if disease burden is 
measured in terms of socioeconomic costs. Kim’s study 
also measured cancer-related direct costs of 3.0 trillion 
won (30.4%) in 2005, whereas the indirect costs were 10.7 
trillion won (76.3%). In particular, , the mortality costs 
are much greater than the morbidity costs for cancers in 
which survival rates are relatively low compared with 
other diseases. Similarly, in the case of DALY, which are 
measured as the sum of YLLs and YLDs, YLLs were much 
larger than YLDs except in thyroid cancer. There were 
similar results in Park’s study (Park and Park, 2012; Park 
et al., 2013). The mortality costs of certain diseases tend 
to be observed at younger ages and lower survival rates 
(Romeder and Mcwhinnie, 1977; Jung, 2011). 
Comparison of SMCB in two studies showed that 
the burden of lung cancer was relatively large, and the 
burden of liver cancer was relatively small. Both studies 
determined that the burden of liver cancer was greater than 
that of lung cancer. This is why cancer burden by a single 
measure is reflected as an estimate of both incidence and 
mortality. However, these two studies tended to show that 
premature death costs were larger if cancer burden was 
larger. The greatest cancer burden according to SMCB 
and DALY in 2005 was for stomach cancer, whereas 
socioeconomic costs were greatest for liver cancer. 
These findings may be explained by the age-specific 
cancer mortality in 2005 (Ministry of Health And Welfare, 
2013a). Mortality from liver cancer was higher than from 
stomach and lung cancers in patients whose ages ranged 
from 40-75. Mortality rates from stomach and lung cancers 
were higher than those for liver cancer starting at age 75. 
Therefore, the premature costs and YLLs of liver cancer 
were larger than those for stomach and lung cancers, which 
affected the burden of liver cancer. 
Both studies reflected early death based on cancer 
burden. The burden of stomach cancer was ranked at the 
top by DALY, and the burden of liver cancer was ranked 
at the top by socioeconomic costs. Unique features 
of each measurement method were also considered. 
Socioeconomic costs were estimated by considering 
individual characteristics, such as unemployment rates, 
employment rates, and average wages according to sex. 
DALY were estimated by taking incidence and mortality 
into consideration for male and female populations. The 
incidence and mortality rates of stomach cancer in males 
were 76.4 and 36.1 people per 100,000, respectively. The 
incidence and mortality rates of liver cancer were 49.3 
and 37.5 people per 100,000, respectively, in 2005. The 
incidence and mortality rates of stomach cancer in females 
were 32.4 and 13.3 people per 100,000, respectively. The 
incidence and mortality rates of liver cancer were 13.2 and 
9.7 people per 100,000, respectively. The incidence of 
stomach cancer in males was twice as high as in females, 
Kyoung-Hee Cho et al
Asian Pacific Journal of Cancer Prevention, Vol 14, 20135254
and mortality was three times higher in males versus 
females. The incidence and mortality of liver cancer was 
three times higher in males than in females. The burden 
of liver cancer was larger than that of stomach cancer 
according to socioeconomic costs, because employment 
rates and average wages were usually larger for males 
than females in Korea. 
In addition, stomach cancer burden showed a 
significant increase annually from 1999 to 2010 in Korea 
according to DALY. In contrast, lung cancer burden 
significantly increased according to SMCB. There are 
two potential explanations for these findings. First, the 
proportion of people who are 65 years old or greater has 
progressed rapidly from 7.2% to 11.1% during 2000-
2010. Second, the incidence and mortality rates of lung 
cancer were relatively higher than those for stomach 
cancer in aging people. Therefore, lung cancer burden 
was highlighted by SMCB, which equally reflected age 
structure.
Premature costs and YLLs were relatively small for 
thyroid cancer in comparison to other cancers, as the 
survival rate was close to 100%. DALY for thyroid cancer 
were as small as 14 person-years. YLDs were small, 
because the disability weight of thyroid cancer was low.
DALY measurements consider age-weighting and 
socioeconomic burden, which focus on employment 
and manpower of housework as features that are 
important to the health status of young people. DALY 
and socioeconomic burden have raised criticism for 
highlighting younger generations. In contrast, there is a 
feature of SMCB that reflects age structure equally. SMCB 
with this feature is valuable for developed countries 
like Korea where the survival rate increases rapidly and 
characteristics of chronic disease are reinforced in cancer.
In conclusion, the single measure developed in this 
study was based equally on incidence and mortality. This 
was a significant difference from the other two studies. 
Development of the single measure did not involve 
adding incidence and mortality alone. We set a range of 
10 by equal intervals based on the maximum value in 
the whole population, including males and females. We 
assigned scores according to incidence and mortality by 
range and added the scores. Mortality showed a tendency 
to be lower than incidence. If incidence and mortality 
were added alone, mortality would be reflected less than 
incidence. Thereby, we added scores for incidence and 
mortality by range to make the dimensions of incidence 
and mortality the same. We considered using both 
equal interval and standard deviation for determining 
rankings by cancer sites. The distribution was skewed to 
the right when distributions of incidence and mortality 
were examined by year and cancer site. Respective 
incidence and mortality were converted to logarithmic 
scale, and normal distributions were made. Rank was 
determined with the standard deviation. In comparison to 
equal interval, standard deviation is affected less by the 
maximum value. However, conversion to logarithmic scale 
tended to make larger values smaller and smaller values 
larger due to the nature of logarithmic scales. Logarithmic 
conversion was useful for cancers that had low incidence 
and low mortality. However, the disadvantage was that the 
actual difference between cancer sites was not adequately 
reflected. Cancers were concentrated on both sides of the 
average value. In contrast, in the case of equal intervals, 
the disadvantage was that these values were affected more 
by the maximum value. The advantage was that equal 
intervals reflected the actual difference.
 Another consideration in developing a single measure 
was whether to add or multiply scores. The advantage of 
multiplying scores is that the burden by cancer site was 
dramatic. In contrast, the disadvantage is that multiplied 
scores are more affected by large or small values on one 
side, because respective scores of incidence and mortality 
are weighted together. However, in the case of adding 
scores, the disadvantage is that differences in cancer-
specific burden are not dramatic. The advantage is that 
adding scores would adequately reflect the equivalent 
size of scores, which would be consistent with the original 
purpose.
The purpose of developing a single measure was 
not to compare cancers that had small cancer burdens 
but to determine the priority of cancer-specific burden. 
Therefore, equal interval reflected actual cancer-specific 
differences more than standard deviation, and adding 
scores was more suitable than multiplying scores.
The other consideration was how to determine rank for 
cancers with the same SMCB. For example, the burdens of 
breast cancer and thyroid cancer were the same in females. 
The score for breast cancer was 11 points with 8 points 
for incidence and 3 points for mortality. The score for 
thyroid cancer was 11 points with 10 points for incidence 
and 1 point for mortality. Breast cancer had a certain size 
for incidence and mortality. The growth rate for thyroid 
cancer burden was greater. We should determine whether 
to select a certain size for both incidence and mortality or 
to select a greater growth rate for cancer burden. The first 
purpose of this study was to judge cancer-specific burden 
through the average approach. In cases that had the same 
cancer burden, we decided that selecting a certain size for 
both incidence and mortality was greater. However, this 
does not mean that cancer burden is small. The growth of 
cancer burden grows rapidly each year, which is a subject 
to be considered as a sentinel indicator. 
The limitations of this study were that a single 
measure was affected by the maximum value and did 
not differentiate between cancers that had small cancer 
burdens. Nevertheless, a single measure is meaningful 
in that it can easily be used by anyone to determine the 
cancer-specific burden. Furthermore, this study was 
meaningful, because it was the first study in which 
epidemiologic cancer burden was comprehensively 
examined with a single measure that considered both 
incidence and mortality. 
An SMCB that reflects age structure equally is useful 
as an alternative indicator for policy makers, because we 
are currently faced with an aging society.
In conclusion, this study developed SMCB that 
indicated the burdens of cancers through merging 
incidence and mortality. DALY measurements consider 
age-weighting and socioeconomic burden, which focus 
on employment and manpower of housework as features 
that are important to the health status of young people. 
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Merging Cancer Incidence and Mortality Data in a Single Measure in Korea
DALY and socioeconomic burden have raised criticism 
for highlighting younger generations. In contrast, there is a 
feature of SMCB that reflects age structure equally. SMCB 
with this feature is valuable for developed countries 
like Korea where the survival rate increases rapidly and 
characteristics of chronic disease are reinforced in cancer. 
We consider that SMCB is useful for policy-makers of 
developed countries.
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